The effect of lacosamide on calcitonin gene-related peptide serum level in episodic migraine patients: a randomized, controlled trial

What Was Tested

Researchers studied CGRP (Calcitonin Gene-Related Peptide) in the context of migraine in this randomized controlled trial publication.

The primary outcome was the difference in the serum level of CGRP-LI after three months of treatment with either lacosamide and ibuprofen or ibuprofen alone in episodic migraine patients.

Why It Was Studied

The researchers registered their trial on ClinicalTrials.gov, named after "The Lacosamide's Effect on Calcitonin Gene-related Peptide in Migraine Patients," and with a clinical trial number (NCT05632133)-August 8, 2023.

Who Took Part

The age groups tagged for this paper are children, teenagers, young adults, adults and middle-aged adults, both men and women.

The researchers conducted an open-label randomized controlled trial on episodic migraine patients aged 10-55 years diagnosed according to (ICHD-3) in Kafr El-Sheikh University Hospital, Egypt.

The researchers assessed serum levels of CGRP-LI before and three months after treatment in their two groups, the lacosamide, and the control groups.

How the Study Was Run

The researchers set it up as a randomized and open-label study.

Because people in this CGRP (Calcitonin Gene-Related Peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Being open-label, the CGRP (Calcitonin Gene-Related Peptide) study did not mask who received what.

What Was Measured

The subject headings attached to it are Lacosamide, Migraine Disorders and Calcitonin Gene-Related Peptide.

Author keywords: Egypt and Episodic migraine.

What This Means in Plain Language

The paper is a randomized and open-label study of CGRP (Calcitonin Gene-Related Peptide) in people with migraine.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2024 (Acta neurologica Belgica), a journal based in Italy.

More context: the CGRP (Calcitonin Gene-Related Peptide) compound page, Migraine research.